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Significance & InnovationsThe multidimensional health assessment questionnaire (MDHAQ), which is informative in all rheumatic diseases studied, can be useful to screen for fibromyalgia (FM) in busy clinical settings.Several scales and indices derived from the MDHAQ are comparable to 2011 FM criteria in screening for FM, regardless of primary rheumatic disease diagnosis.The more pragmatic cumulative indices perform similarly to continuous indices and are far less cumbersome to calculate.

Introduction {#acr211053-sec-0006}
============

Fibromyalgia (FM) is common in the general population [1](#acr211053-bib-0001){ref-type="ref"}, [2](#acr211053-bib-0002){ref-type="ref"} and is even more common in people with rheumatic conditions [3](#acr211053-bib-0003){ref-type="ref"}, [4](#acr211053-bib-0004){ref-type="ref"}, [5](#acr211053-bib-0005){ref-type="ref"}. FM often is easily recognized but may be difficult to identify in some patients, particularly those with other diagnoses such as rheumatoid arthritis (RA), osteoarthritis (OA), systemic lupus erythematosus (SLE), and others. FM classification criteria were reported in 1990 [6](#acr211053-bib-0006){ref-type="ref"}, revised in 2010 [7](#acr211053-bib-0007){ref-type="ref"}, and endorsed by the American College of Rheumatology (ACR). Further revised criteria were reported in 2011 [8](#acr211053-bib-0008){ref-type="ref"} and 2016 [9](#acr211053-bib-0009){ref-type="ref"}, based only on patient self‐report questionnaires, were termed "diagnostic criteria," and were not endorsed by the ACR [10](#acr211053-bib-0010){ref-type="ref"}.

FM criteria are used in clinical trials and other clinical research but generally not in routine care. It is not feasible for office staff to ask patients with different diagnoses to complete different self‐report questionnaires in busy clinical settings [11](#acr211053-bib-0011){ref-type="ref"}. Patients with FM may have high scores on indices designed to assess disease activity in RA and other diseases, which may not reflect disease activity. For example, a patient with no swollen joints and an erythrocyte sedimentation rate (ESR) of 10 mm/hr (suggesting no inflammatory activity), but a tender joint count of 18/28, a pain visual analog scale (VAS) of 8, and a patient global assessment (PATGL) of 8 would have a disease activity score (DAS28) [12](#acr211053-bib-0012){ref-type="ref"} of 5.1, a clinical disease activity index (CDAI) [13](#acr211053-bib-0013){ref-type="ref"} of 36, and a routine assessment of patient index data (RAPID3) score [14](#acr211053-bib-0014){ref-type="ref"} of 20. While these index scores would suggest high activity [13](#acr211053-bib-0013){ref-type="ref"}, [14](#acr211053-bib-0014){ref-type="ref"}, [15](#acr211053-bib-0015){ref-type="ref"}, [16](#acr211053-bib-0016){ref-type="ref"}, the patient would not be a candidate for initiation or intensification of therapy with biological agents. Such patients may present apparent anomalies for the treat‐to‐target approach [17](#acr211053-bib-0017){ref-type="ref"}, which may be explained, however, when the basis for nonintensification is recognized [18](#acr211053-bib-0018){ref-type="ref"}.

A more feasible approach than the FM criteria questionnaire to screen for FM in routine care might be available from a multidimensional health assessment questionnaire (MDHAQ) [19](#acr211053-bib-0019){ref-type="ref"}, [20](#acr211053-bib-0020){ref-type="ref"}, which has been reported previously to provide clues to FM [21](#acr211053-bib-0021){ref-type="ref"}, [22](#acr211053-bib-0022){ref-type="ref"}. The MDHAQ/RAPID3 has been documented to be sensitive to changes in clinical status in all rheumatic diseases studied [23](#acr211053-bib-0023){ref-type="ref"}, [24](#acr211053-bib-0024){ref-type="ref"}, including OA [25](#acr211053-bib-0025){ref-type="ref"}, SLE [25](#acr211053-bib-0025){ref-type="ref"}, [26](#acr211053-bib-0026){ref-type="ref"}, ankylosing spondylitis [25](#acr211053-bib-0025){ref-type="ref"}, [27](#acr211053-bib-0027){ref-type="ref"}, [28](#acr211053-bib-0028){ref-type="ref"}, [29](#acr211053-bib-0029){ref-type="ref"}, [30](#acr211053-bib-0030){ref-type="ref"}, psoriatic arthritis [31](#acr211053-bib-0031){ref-type="ref"}, gout [25](#acr211053-bib-0025){ref-type="ref"}, vasculitis [32](#acr211053-bib-0032){ref-type="ref"}, and polymyalgia rheumatica [33](#acr211053-bib-0033){ref-type="ref"}. The MDHAQ also includes a fatigue VAS; queries concerning sleep quality, anxiety, and depression; a self‐report painful joint count [34](#acr211053-bib-0034){ref-type="ref"} similar to the FM criteria widespread pain index (WPI); and a symptom checklist which includes items found on the FM criteria symptom severity scale (SSS). In this report, we analyze the capacity of various MDHAQ‐derived indices, compared with the 2011 FM criteria as the reference standard, to screen for FM [10](#acr211053-bib-0010){ref-type="ref"}.

Patients and methods {#acr211053-sec-0007}
====================

 {#acr211053-sec-0008}

### Patients {#acr211053-sec-0009}

All consecutive patients (with all diagnoses) seen for rheumatology care at Rush University are asked to complete an MDHAQ [19](#acr211053-bib-0019){ref-type="ref"}, [20](#acr211053-bib-0020){ref-type="ref"} at each rheumatology visit in routine care. In April 2017, the 2011 revised FM criteria questionnaire [8](#acr211053-bib-0008){ref-type="ref"} was added to the MDHAQ for completion by all unselected patients with any condition who were not new to the clinic (new patients complete a long MDHAQ version that queries past history) and could complete English‐language questionnaires (the FM questionnaire was available only in English).

The RAPID3 index on the MDHAQ is composed of three 0‐10 scores for physical function, pain, and patient global assessment [14](#acr211053-bib-0014){ref-type="ref"}, [16](#acr211053-bib-0016){ref-type="ref"}, [35](#acr211053-bib-0035){ref-type="ref"}, [36](#acr211053-bib-0036){ref-type="ref"}. At our institution, questionnaires are routinely distributed to all patients but are reviewed and scored variably by different physicians and even by the same physician. Although they had access to the patients' FM criteria questionnaire responses, the 13 faculty clinicians stated explicitly that they did not review the FM criteria questionnaire when assigning specific primary and secondary diagnoses according to *International Classification of Diseases, 10th Revision* (ICD‐10) codes. In analyses of proposed FM indices based on MDHAQ scales (termed "MDHAQ‐FM" indices), patients were identified as having FM according to three methods: 1) physician‐entered FM ICD‐10 code in the medical record as a primary or secondary diagnosis, 2) the 2011 modified FM criteria, the primary reference criteria, and 3) the 2016 modified FM criteria.

### Institutional approval {#acr211053-sec-0010}

The Rush University Institutional Review Board (IRB) waived a requirement for patient consent in completion of patient questionnaires because the questionnaire is a component of routine care, analogous to a laboratory test, for quantitative data to guide clinical decisions [37](#acr211053-bib-0037){ref-type="ref"}. The Rush University IRB approved the addition of the FM criteria questionnaire to the MDHAQ for routine care. The IRB approved a retrospective review of routine care questionnaires, provided the data were de‐identified of protected information concerning patient name, medical record number, and date of birth. The study was conducted in accordance with the Helsinki Declaration.

### Patient questionnaires {#acr211053-sec-0011}

*FM criteria questionnaire*. The FM criteria questionnaire is composed of two scales: the symptom severity scale (SSS) and the widespread pain index (WPI) [8](#acr211053-bib-0008){ref-type="ref"}. The SSS queries for six symptoms; three, fatigue, waking unrefreshed, and cognitive symptoms, are scored from 0 to 3 (total: 0‐9); three others, headaches, pain or cramps in the lower abdomen, and depression, are scored 0  or 1 (total: 0‐3) (total SSS scores = 0‐12). The WPI queries for 19 painful joints or other body regions, each scored as 0 or 1 (total: 0‐19). The sum of the SSS (0‐12) and the WPI (0‐19) scores is termed a polysymptomatic distress scale (PSD) (total: 0‐31) [38](#acr211053-bib-0038){ref-type="ref"}. A patient meets 2011 FM criteria if the WPI score is greater than or equal to 7 and the SSS score is greater than or equal to 5 or if the WPI score is 3‐6 and the SSS score is greater than or equal to 9 [8](#acr211053-bib-0008){ref-type="ref"}.

The 2016 modification of the 2011 FM criteria introduced two changes: a requirement for pain in 4 of 5 bodily regions, introduced because patients with regional pain syndromes may be misclassified as having FM according to 2011 criteria [9](#acr211053-bib-0009){ref-type="ref"}, and a statement that the same criteria are applied to "primary" and "secondary" FM. The 2011 criteria appear more informative in rheumatology settings [9](#acr211053-bib-0009){ref-type="ref"}, [10](#acr211053-bib-0010){ref-type="ref"} and were chosen as the reference standard [10](#acr211053-bib-0010){ref-type="ref"}, although some descriptive analyses involving the 2016 criteria are presented.

*MDHAQ*. The MDHAQ [19](#acr211053-bib-0019){ref-type="ref"}, [20](#acr211053-bib-0020){ref-type="ref"} is a two‐page single‐sheet questionnaire developed from the Stanford health assessment questionnaire (HAQ) [39](#acr211053-bib-0039){ref-type="ref"} in clinical care as a continuous quality improvement program [40](#acr211053-bib-0040){ref-type="ref"}. The MDHAQ includes a 0‐10 score for physical function, pain, and patient global assessment, compiled into a 0‐30 RAPID3 score, as well as scales for fatigue, rheumatoid arthritis disease activity index (RADAI) self‐report painful joint count [34](#acr211053-bib-0034){ref-type="ref"}, and a 60‐symptom checklist. Although developed initially in studies of patients with RA, MDHAQ/RAPID3 has been found to be informative in OA, SLE, FM, ankylosing spondylitis, psoriatic arthritis, and polymyalgia rheumatica, in addition to RA and other rheumatic diseases [24](#acr211053-bib-0024){ref-type="ref"}, [25](#acr211053-bib-0025){ref-type="ref"}.

The MDHAQ physical function scale includes 10 activities: 8 from the original standard HAQ [39](#acr211053-bib-0039){ref-type="ref"} and 2 complex activities [19](#acr211053-bib-0019){ref-type="ref"}, [20](#acr211053-bib-0020){ref-type="ref"} scored 0‐3, as in the HAQ [39](#acr211053-bib-0039){ref-type="ref"} a total of 0‐30 recalculated to 0‐10. The MDHAQ physical function section also includes queries concerning sleep quality, anxiety, and depression in the patient‐friendly HAQ format. Pain and PATGL VASs are in 21 circles at 0.5 intervals [41](#acr211053-bib-0041){ref-type="ref"}. Three 0‐10 scores for function, pain, and PATGL are compiled into a 0‐30 RAPID3 score using a template on the MDHAQ [42](#acr211053-bib-0042){ref-type="ref"}.

The two‐page MDHAQ also includes a 0‐10 fatigue VAS and a self‐report painful joint count termed the rheumatoid arthritis disease activity index (RADAI) [34](#acr211053-bib-0034){ref-type="ref"}. The eight symmetrical joint groups (fingers, wrists, elbows, shoulders, hips, knees, ankles, and toes) are scored for pain as a graded scale, 0 = none, 1 = mild, 2 = moderate, and 3 = severe for a total score of 0‐48, or as a binary sacle, 0 = none, 1 = pain present for a total score of 0‐16. The MDHAQ version of the RADAI self‐report painful joint count adds the neck and back, which are scored in a graded or binary format for a total score of 0‐54 or 0‐18. The MDHAQ contains a 60‐symptom checklist, which includes items similar to the SSS: fatigue, problems with sleeping, problems with thinking, problems with memory, depression, and stomach pain. Demographic data on the MDHAQ include date of birth, sex, ethnicity, and years of formal education.

### MDHAQ‐FM derived indices {#acr211053-sec-0012}

Two approaches were used to develop four MDHAQ‐derived FM indices, which were then compared with the 2011 FM criteria as the external standard. The first approach was to construct a continuous index composed of the MDHAQ items that were similar to the FM criteria items, termed the "MDHAQ‐FM‐PSD." For this approach, the MDHAQ self‐report painful joint count was regarded as analogous to the FM‐WPI and was termed the "MDHAQ‐FM‐WPI," and items on the symptom checklist and other scales that queried for the same symptoms as the SSS were compiled into an "MDHAQ‐FM‐SSS" index. The arithmetic sum of the MDHAQ‐FM‐SSS and MDHAQ‐FM‐WPI was termed the MDHAQ‐FM‐PSD.

The second approach involved a compilation of MDHAQ scores into a cumulative index, as more easily‐calculated and feasible in busy clinical settings than a continuous MDHAQ‐FM‐PSD. Initially, 10 MDHAQ candidate scores were evaluated for their area under the curve (AUC) in receiver operating characteristic (ROC) curve analyses using the 2011 criteria as the external standard: physical function (0‐10), pain VAS (0‐10), PATGL VAS (0‐10), RAPID3 (0‐30), fatigue VAS (0‐10), sleep quality (0‐3.3), anxiety (0‐3.3), depression (0‐3.3), RADAI self‐report painful joint count (0‐48, 0‐54, 0‐16, or 0‐18, as noted above), and symptom checklist (0‐60). The four scores with the highest AUCs were compiled into indices of three or four individual scores, termed fibromyalgia assessment screening tools, FAST3 or FAST4, respectively. RAPID3 and PATGL were not included in FAST indices because clinical observations had suggested that they were more likely to reflect somatic symptoms such as fever or dyspnea.

### Statistical analyses {#acr211053-sec-0013}

All analyses were performed in Stata version 12.0 for Macintosh (StataCorp LP). The proportion of patients with FM (primary or secondary) defined as physician‐entered ICD‐10 code and the proportion of patients with FM who met the 2011 and 2016 criteria for FM were computed. Demographic and clinical characteristics were compared in patients who met or did not meet the 2011 FM criteria. Means and SDs were compared using *t* tests, and percentages were compared using χ^2^ tests.

Spearman rank‐order correlation coefficients were calculated between the individual items on the MDHAQ and FM criteria questionnaire counterparts to evaluate construct validity. Correlations between the SSS, WPI, and total PSD from the FM questionnaire (the sum of the WPI and SSS scores) and a composite total MDHAQ‐FM‐SSS, MDHAQ‐FM‐WPI, and MDHAQ‐FM‐PSD were computed.

To develop cumulative FAST indices,10 MDHAQ scores were analyzed using ROC curves versus the 2011 FM criteria as the external standard to identify measures with highest AUC. FAST3 and FAST4 indices were constructed from the three or four scores with the highest AUCs for individual MDHAQ items. Cumulative indices include a 0 or 1 score for each of three or four variables with the highest AUC, based on the optimal "trade‐off" between sensitivity and specificity. Agreement of the MDHAQ‐derived continuous and cumulative indices withthe 2011 FM criteria and clinical diagnosis was assessed by kappa statistics [43](#acr211053-bib-0043){ref-type="ref"}. Indices were also analyzedusing Spearman correlations with the 2011 FM criteria for the SSS, WPI, and PSD.

Results {#acr211053-sec-0014}
=======

 {#acr211053-sec-0015}

### Patient diagnoses from medical record {#acr211053-sec-0016}

Among 502 patients with complete data, 106 (21%) were identified by ICD‐10 codes as having primary or secondary FM, 131 (26%) met the 2011 FM criteria, and 112 (22%) met the 2016 FM criteria (Table [1](#acr211053-tbl-0001){ref-type="table"}). Primary ICD‐10 diagnoses included FM in 49 patients, OA in 74 patients, RA in 78 patients, SLE in 88 patients, and other rheumatic diseases in 213 patients (Table [1](#acr211053-tbl-0001){ref-type="table"}). Median RAPID3 scores were 18.7 in patients with FM, 15.0 in patients with OA, 13.3 in patients with RA, 10.0 in patients with SLE, and 9.8 in the remaining patients (Table [1](#acr211053-tbl-0001){ref-type="table"}).

###### 

Diagnoses as charted by physicians compared to FM status by 2011 and 2016 modified criteria

  Primary Diagnosis According to Physician   Total, N (%)   Median RAPID3 Score, (Interquartile Range)   Diagnosed With FM by the Physician, n (%)   2011 FM Criteria Positive, n (%)   2016 FM Criteria Positive, n (%)
  ------------------------------------------ -------------- -------------------------------------------- ------------------------------------------- ---------------------------------- ----------------------------------
  FM                                         49 (10)        18.7 (15.2‐22.7)                             49 (100)                                    33 (67)                            29 (59)
  OA                                         74 (15)        15.0 (11.5‐19.8)                             15 (20)                                     24 (32)                            20 (27)
  RA                                         78 (15.5)      13.3 (5.3‐17.7)                              8 (10)                                      14 (18)                            12 (15)
  SLE                                        88 (17.5)      10.0 (3.5‐16.3)                              9 (10)                                      17 (19)                            15 (17)
  Other                                      213 (42)       9.8 (5‐16.7)                                 25 (12)                                     43 (20)                            36 (15)
  Total                                      502 (100)      12.7 (5.8‐17.7)                              106 (21)                                    131 (26)                           112 (22)

Abbreviation: FM, fibromyalgia; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

John Wiley & Sons, Ltd

Among the 49 patients with primary FM per ICD‐10, 33 (67%) met the 2011 FM criteria and 29 (59%) met the 2016 FM criteria. Among patients assigned a primary diagnosis of RA, OA, and SLE, 10%, 20%, and 10%, respectively, also were assigned a diagnosis of FM (secondary) per ICD‐10, whereas 11%, 32%, and 19%, respectively, met the 2011 FM criteria, and 15%, 27%, and 17%, respectively, met the 2016 FM criteria. More patients were assigned a primary diagnosis of FM per ICD‐10 than those who met 2011 or 2016 FM criteria, whereas a reciprocal pattern was seen for patients with other primary diagnoses and comorbid or secondary FM (Table [1](#acr211053-tbl-0001){ref-type="table"}).

### MDHAQ measures according to 2011 FM criteria {#acr211053-sec-0017}

MDHAQ measures were compared in 131 patients with FM per the 2011 FM criteria versus the other 371 patients (Table [2](#acr211053-tbl-0002){ref-type="table"}). Differences in age and ethnicity were marginally significant but not clinically important (*P* = 0.05). Differences in sex were significant (*P* = 0.004), reflecting that women generally score higher on all self‐report questionnaire scales [44](#acr211053-bib-0044){ref-type="ref"}. Differences in formal education, 13.8 vs 14.8 years in patients who met FM criteria versus those who did not (*P*= 0.001), were significant, consistent with evidence that most clinical measures differ more by education level than by age [45](#acr211053-bib-0045){ref-type="ref"}. All clinical MDHAQ scores studied were  clinically and statistically significantly higher in patients who met 2011 FM criteria than in patients who did not meet these criteria, including scores for physical function, pain VAS, PATGL VAS, RAPID3 (by definition based on individual component scores), sleep quality, anxiety, depression, fatigue VAS, RADAI self‐report painful joint count, and symptom checklist (Table [2](#acr211053-tbl-0002){ref-type="table"}).

###### 

Demographic and clinical measures on the MDHAQ versus the 2011 FM criteria[a](#acr211053-note-0006){ref-type="fn"}

                                                 Total (N = 502)   FM 2011 Criteria   *P*           
  ---------------------------------------------- ----------------- ------------------ ------------- ---------
  Demographic measures                                                                               
  Age, years                                     52.6 (16.3)       50.2 (15.8)        53.5 (16.4)   0.05
  Female sex                                     415 (83%)         119 (90%)          296 (80%)     0.004
  Race and/or ethnicity                                                                              
  White                                          195 (46%)         47 (46%)           148 (47%)     0.05
  Black                                          140 (33%)         30 (29%)           110 (35%)     ...
  Hispanic                                       69 (16%)          23 (22%)           46 (15%)      ...
  Asian                                          15 (4%)           2 (2%)             13 (4%)       ...
  Formal education, years                        14.6 (3.1)        13.8 (3.4)         14.8 (3.0)    0.001
  Clinical measures                                                                                  
  Physical function (0‐10)                       2.4 (2.1)         4.1 (1.9)          1.8 (1.8)     \<0.001
  Pain VAS (0‐10)                                5.1 (3.1)         7.7 (1.8)          4.2 (2.9)     \<0.001
  Global VAS (0‐10)                              4.7 (2.9)         7.1 (1.9)          3.9 (2.7)     \<0.001
  Fatigue VAS (0‐10)                             4.8 (3.3)         7.8 (1.9)          3.7 (3.0)     \<0.001
  RAPID3 (0‐30)                                  12.3 (7.3)        18.8 (4.6)         10.1 (6.7)    \<0.001
  RADAI self‐report painful joint count (0‐54)   11.1 (10.8)       21.9 (11.0)        7.3 (7.6)     \<0.001
  Symptom checklist (0‐60)                       11.9 (9.4)        22.0 (9.3)         8.3 (6.2)     \<0.001
  Sleep quality (0‐3.3)                          1.2 (1.0)         2.0 (0.9)          0.9 (0.9)     \<0.001
  Anxiety (0‐3.3)                                0.7 (0.8)         1.2 (0.9)          0.5 (0.7)     \<0.001
  Depression (0‐3.3)                             0.6 (0.8)         1.2 (0.9)          0.4 (0.7)     \<0.001

Abbreviation: FM, fibromyalgia; MDHAQ, multidimensional health assessment questionnaire; RADAI, rheumatoid arthritis disease activity index; RAPID3, routine assessment of patient index data; VAS, visual analog scale.

Ordinal variables are presented as absolute number (percentage), and continuous variables are presented as mean (SD).
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### MDHAQ scales compared with FM criteria {#acr211053-sec-0018}

Table [3](#acr211053-tbl-0003){ref-type="table"} includes MDHAQ items that query similar constructs in different scales (eg, depression on a 0‐3.3 scale in the HAQ format and as 0‐1 symptom among 60 in the symptom checklist). Correlation coefficients of the six individual components of the SSS and their MDHAQ counterparts were highly significant (Table [3](#acr211053-tbl-0003){ref-type="table"}) and were consistently higher between the identical or nearly identical pairs than between the other five items, with the exception of fatigue and waking up unrefreshed on the FM criteria SSS and fatigue and sleep quality in two measures each on the MDHAQ (Table [3](#acr211053-tbl-0003){ref-type="table"}). For the final continuous indices, the individual items with the highest correlation were chosen. The correlation coefficient between the SSS from the FM criteria and a summary index derived from the six corresponding MDHAQ items, termed MDHAQ‐FM‐SSS, was rho = 0.869 (Table [3](#acr211053-tbl-0003){ref-type="table"}).

###### 

Spearman correlations between individual components of the 2011 revised FM criteria and MDHAQ items[a](#acr211053-note-0008){ref-type="fn"}

                                                                  MDHAQ Items                                                                                                                                                                                                           
  --------------------------------------------------------------- --------------- --------------------------- -------------------------------------- --------------------------------------------------- ------------- ----------------- --------------------------- ------------------ --------------------
  Between SSS and MDHAQ[b](#acr211053-note-0009){ref-type="fn"}                                                                                                                                                                                                                         
                                                                  Fatigue (0‐3)   Fatigue (0‐1)               Problems With Thinking/Memory (0‐2)    Good Night\'s Sleep (0‐3.3)                         Sleep (0‐1)   Headaches (0‐1)   Stomach Pain/Cramps (0‐1)   Depression (0‐1)   Depression (0‐3.3)
  SSS items                                                                                                                                                                                                                                                                              
  Fatigue (0‐3)                                                   0.779           0.556                       0.431                                  0.571                                               0.422         0.303             0.300                       0.377              0.449
  Trouble thinking or remembering (0‐3)                           0.497           0.373                       0.737                                  0.446                                               0.432         0.315             0.385                       0.449              0.542
  Waking up unrefreshed (0‐3)                                     0.676           0.421                       0.432                                  0.641                                               0.512         0.330             0.343                       0.356              0.444
  Headaches (0‐1)                                                 0.349           0.268                       0.288                                  0.252                                               0.243         0.718             0.259                       0.247              0.265
  Pain/cramps in lower abdomen (0‐1)                              0.309           0.236                       0.307                                  0.272                                               0.221         0.308             0.507                       0.267              0.295
  Depression (0‐1)                                                0.411           0.258                       0.432                                  0.321                                               0.412         0.326             0.265                       0.704              0.655
  Between WPI and RADAI[c](#acr211053-note-0011){ref-type="fn"}                                                                                                                                                                                                                         
                                                                  RADAI (0‐48)    Dichotomized RADAI (0‐16)   RADAI Including Back and Neck (0‐54)   Dichotomized RADAI Including Back and Neck (0‐18)                                                                                  
  WPI scale                                                       0.733           0.652                       0.753                                  0.703                                                                                                                              

Data are rho values

Abbreviation: FM, fibromyalgia; MDHAQ, multidimensional health assessment questionnaire; PSD, polysymptomatic distress scale (the sum of SSS and WPI scores); RADAI, rheumatoid arthritis disease activity index; SSS, symptom severity scale; WPI, widespread pain index.

The MDHAQ‐SSS is sum of fatigue (0‐3), problems with thinking/memory (0‐2), good night\'s sleep (0‐3.3), headaches (0‐1), stomach pain/cramps (0‐1), and depression (0‐1) scores; The MDHAQ‐WPI is the self‐report joint count, including the back and neck (0‐54), divided by 3 (0‐18); The MDHAQ‐PSD is the sum of MDHAQ‐SSS and MDHAQ‐WPI scores.

The correlation between composites of 6 MDHAQ somatic symptoms (MDHAQ‐FM‐SSS) and SSS = 0.869.

The correlation between MDHAQ‐FM‐PSD (MDHAQ‐FM‐WPI + MDHAQ‐FM‐SSS) and PSD = 0.864.
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Correlations between the WPI from the FM criteria and each of the four versions of the RADAI self‐report painful joint count ranged from rho = 0.652 to rho= 0.753 (Table [3](#acr211053-tbl-0003){ref-type="table"}), highest for the version with 0‐3 scoring and the back and neck added to the original scale (Table [3](#acr211053-tbl-0003){ref-type="table"}). The summary correlation between the PSD (the sum of SSS and WPI scores in the ACR criteria) and the MDHAQ equivalent composed of the sum of the MDHAQ‐FM‐SSS and MDHAQ‐FM‐WPI scores, termed the MDHAQ‐FM‐PSD, was rho = 0.864 (Table [3](#acr211053-tbl-0003){ref-type="table"}).

The optimal cut point for the MDHAQ‐FM‐WPI and MDHAQ‐FM‐SSS, based on ROC analyses (Figure [1](#acr211053-fig-0001){ref-type="fig"}A), was 5 for each scale, resulting in an AUC versus the 2011 FM criteria of 0.881 for the MDHAQ‐WPI and of 0.916 for the MDHAQ‐SSS (Table [4](#acr211053-tbl-0004){ref-type="table"}). An MDHAQ‐PSD score greater than or equal to 10 had an AUC of 0.929 (Table [4](#acr211053-tbl-0004){ref-type="table"}), which correctly classified 85.1% of patients (data not shown).

![**a**, Receiver operating characteristic (ROC) curves for the multidimensional health assessment questionnaire (MDHAQ) single items to screen for fibromyalgia (FM) according to the 2011 FM criteria as a reference standard. The four single items showing a higher area under the curve (AUC) are in bold: symptom checklist, rheumatoid arthritis disease activity index (RADAI) self‐report painful joint count (JC), fatigue visual analog scale (VAS), and pain VAS. ROC curves to compare the capacity of all MDHAQ‐based composite indices and routine assessment of patient index data (RAPID3) to discriminate between patients with or without FM according to the 2011 revised criteria (**b**) and according to the physicians' diagnosis of FM (**c**) as a reference standard. The MDHAQ‐FM‐SSS is the sum of fatigue, problems with thinking/memory, good night sleep, headaches, stomach pain/cramps, and depression scores. The MDHAQ‐FM‐WPI is the self‐report painful joint count, which includes the back and neck (0‐54), divided by 3. The MDHAQ‐FM‐PS is the sum of the MDHAQ‐SSS and the MDHAQ‐WPI. FAST3‐P, (fibromyalgia assessment screening tool cumulative index) includes pain, self‐report painful joint count, and symptom checklist; FAST4 (fibromyalgia assessment screening tool cumulative index) includes pain, fatigue, self‐report painful joint count, and symptom checklist; SSS, symptom severity scale.](ACR2-1-516-g001){#acr211053-fig-0001}

###### 

Performance characteristics of MDHAQ individual scores (MDHAQ‐FM indices versus 2011 FM criteria as reference standard)[a](#acr211053-note-0013){ref-type="fn"}

                                                 Cut Point   Sensitivity, %   Specificity, %   LR+     AUC of ROC Curves   Correlation vs PSD as a Continuous Variable
  ---------------------------------------------- ----------- ---------------- ---------------- ------- ------------------- ---------------------------------------------
  Pain VAS (0‐10)                                ≥6          85.5             65.0             2.44    0.829               0.639
  Fatigue VAS (0‐10)                             ≥6          84.0             69.6             2.76    0.860               0.692
  RADAI self‐report painful joint count (0‐54)   ≥16         68.7             87.3             5.42    0.877               0.742
  Symptom checklist (0‐60)                       ≥16         77.1             86.3             5.61    0.889               0.785
  MDHAQ‐FM indices                                                                                                          
  MDHAQ‐FM‐SSS (0‐11.3)                          ≥5          79.8             83.3             4.79    0.916               0.808
  MDHAQ‐FM‐WPI (0‐18)                            ≥5          81.6             81.2             4.34    0.881               0.765
  MDHAQ‐FM‐PSD (0‐29.3)                          ≥10         85.6             84.9             5.68    0.929               0.863
  FAST3‐P (0‐3)                                                                                        0.924               0.832
  Pain VAS                                       ≥1          97.7             59.0             2.38    ...                 ...
  Painful joint count                            ≥2          85.5             83.8             5.29    ...                 ...
  Symptom checklist                              3           48.1             95.7             11.15   ...                 ...
  FAST3‐F (0‐3)                                                                                        0.937               0.854
  Fatigue VAS                                    ≥1          97.6             63.1             2.64    ...                 ...
  Painful joint count                            ≥2          83.2             87.9             6.88    ...                 ...
  Symptom checklist                              3           42.4             96.8             13.1    ...                 ...
  FAST4 (0‐4)                                                                                          0.927               0.852
  Fatigue VAS                                    ≥1          98.4             51.6             2.03    ...                 ...
  Pain VAS                                       ≥2          95.2             75.2             3.84    ...                 ...
  Painful joint count                            ≥3          74.4             90.3             7.64    ...                 ...
  Symptom checklist                              4           40.0             96.8             12.33   ...                 ...

Abbreviation: AUC, area under the curve; FAST3‐F, fibromyalgia assessment screening tool cumulative index (includes fatigue, self‐report painful joint count, and symptom checklist); FAST3‐P, fibromyalgia assessment screening tool cumulative index (includes pain, self‐report painful joint count, and symptom checklist); FAST4, fibromyalgia assessment screening tool cumulative index (includes pain, fatigue, self‐report painful joint count, and symptom checklist); FM, fibromyalgia; LR+, positive likelihood ratio; MDHAQ, multidimensional health assessment questionnaire; PSD, polysymptomatic distress scale; RADAI, rheumatoid arthritis disease activity index; ROC, receiver operating characteristic; SSS, symptom severity scale; VAS, visual analog scale; WPI, widespread pain index.

MDHAQ‐FM‐SSS is the sum of fatigue (0‐3), problems with thinking/memory (0‐2), good night\'s sleep (0‐3.3), headaches (0‐1), stomach pain/cramps (0‐1), and depression (0‐1) scores. MDHAQ‐FM‐WPI is the RADAI score, which includes the back and neck (0‐54) score, divided by 3. MDHAQ‐FM‐PSD is the sum of the MDHAQ‐FM‐SSS and MDHAQ‐FM‐WPI scores.
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### Analyses of nine individual MDHAQ scores and RAPID3 versus 2011 FM criteria {#acr211053-sec-0019}

Each of nine candidate single MDHAQ scores and RAPID3 were compared to the 2011 FM criteria according to ROC curves (Figure [1](#acr211053-fig-0001){ref-type="fig"}b), to develop more feasibly‐scored indices based on the MDHAQ for busy clinical settings. The five MDHAQ scores with the highest AUC were the symptom checklist (AUC = 0.891), self‐report RADAI painful joint count (AUC = 0.877), fatigue VAS (AUC = 0.861), RAPID3 (AUC = 0.849), and pain VAS (AUC = 0.828) (Figure [1](#acr211053-fig-0001){ref-type="fig"}a). RAPID3 (and PATGL) was not included in the FAST indices, as noted in the Methods. The optimal trade‐offs of sensitivity and specificity based on the ROC analyses (Figures [1](#acr211053-fig-0001){ref-type="fig"}a and b) were pain VAS (0‐10) greater than or equal to 6, fatigue VAS (0‐10) greater than or equal to 6, self‐report painful joint count (0‐54) greater than or equal to 16, and a symptom checklist (0‐60) greater than or equal to 16. In cumulative composite measures, each component is awarded 0‐1 point based on meeting the prespecified cut point.

A similar approach was used to develop cutoff points for the MDHAQ‐SSS, the MDHAQ‐WPI, and the MDHAQ‐PSD, which is the sum of the MDHAQ‐SSS and MDHAQ‐WPI scores. The optimal trade‐offs of sensitivity and specificity that were selected based on the ROC analyses were an MDHAQ‐FM‐SSS score (0‐11.3) greater than or equal to 5, an MDHAQ‐FM‐WPI score (0‐18) greater than or equal to 5, and an MDHAQ‐FM‐PSD score (0‐29.3) greater than or equal to 10 (Table [4](#acr211053-tbl-0004){ref-type="table"}).

Three FAST cumulative indices were developed from these MDHAQ scales (Table [4](#acr211053-tbl-0004){ref-type="table"}). All includ the symptom checklist and self‐report painful joint count. FAST3‐P adds a pain VAS, FAST3‐F adds a fatigue VAS, and FAST4 includes both a pain VAS and fatigue VAS. All 3 FAST indices agreed with the 2011 FM criteria, with a ROC AUC higher than 0.924 (*P* = 0.21, comparing the three indices) (Table [4](#acr211053-tbl-0004){ref-type="table"}, Figure [1](#acr211053-fig-0001){ref-type="fig"}a).

Correlations of the FAST measures and indices as continuous variables versus the PSD as a continuous variable all were statistically significant and greater than *r* = 0.639 (Table [4](#acr211053-tbl-0004){ref-type="table"}). Correlations of MDHAQ‐FM indices with PSD were higher than those of individual MDHAQ measures with PSD (Table [4](#acr211053-tbl-0004){ref-type="table"}). Correlations of MDHAQ‐FAST3‐P, MDHAQ‐FAST3‐F, and MDHAQ‐FAST4 of *r* = 0.832‐0.854 were almost as high as that of the MDHAQ‐PSD with PSD (*r* = 0.863) (Table [4](#acr211053-tbl-0004){ref-type="table"}).

Kappa values for these indices were 0.63‐0.68 versus the FM 2011 FM criteria, 0.56‐0.60 versus the 2016 FM criteria, and 0.41‐0.45 versus the ICD‐10 diagnosis (Table [5](#acr211053-tbl-0005){ref-type="table"}). Agreement with the 2011 FM criteria of greater than 82% was seen (Table [5](#acr211053-tbl-0005){ref-type="table"}), indicating similar and robust capacity to screen for FM.

###### 

Proportions and agreement between the studied indices and three reference standards: the 2011 FM criteria, the 2016 FM criteria, and the physician\'s diagnosis

  FM Criteria Status          FM 2011 Criteria   FM 2016 Criteria   Physicians' Diagnosis                              
  --------------------------- ------------------ ------------------ ----------------------- ------------- ------------ -------------
  MDHAQ‐FM‐PSD (n = 450)                                                                                                
  Screening positive for FM   101 (66.9%)        50 (33.1%)         87 (57.6%)              64 (42.4%)    74 (49%)     77 (60.1%)
  Screening negative for FM   17 (5.7%)          282 (94.3%)        14 (4.7%)               285 (95.3%)   20 (6.7%)    279 (93.3%)
  Correctly classified        85.1%              82.7%              78.4%                                              
  Kappa (95% CI)              0.65 (0.57‐0.72)   0.58 (0.49‐0.66)   0.47 (0.38‐0.55)                                   
  FAST3‐P (n = 502)                                                                                                     
  Screening positive for FM   112 (85.5%)        60 (16.2%)         96 (55.8%)              16 (4.8%)     82 (47.7%)   90 (52.3%)
  Screening negative for FM   19 (14.5%)         311 (83.8%)        76 (44.2%)              314 (95.1%)   24 (7.3%)    306 (92.7%)
  Correctly classified        84.3%              81.7%              77.3%                                              
  Kappa (95% CI)              0.63 (0.56‐0.70)   0.56 (0.48‐0.63)   0.45 (0.36‐053)                                    
  FAST3‐F (n = 464)                                                                                                     
  Screening positive for FM   104 (83.2%)        41 (12.1%)         89 (82.4%)              56 (15.7%)    68 (68.7%)   77 (21.1%)
  Screening negative for FM   21 (16.8%)         298 (87.9%)        19 (17.6%)              300 (84.3%)   31 (31.3%)   288 (78.9%)
  Correctly classified        86.6%              83.8%              76.7%                                              
  Kappa (95% CI)              0.68 (0.60‐0.75)   0.60 (0.51‐0.68)   0.41 (0.32‐0.50)                                   
  FAST4 (n = 464)                                                                                                       
  Screening positive for FM   93 (73.8%)         32 (9.5%)          81 (64.3%)              27 (7.9%)     63 (50%)     63 (50%)
  Screening negative for FM   33 (26.2%)         306 (90.5%)        45 (35.7%)              311 (92.0%)   36 (10.7%)   302 (89.4%)
  Correctly classisfied       85.9%              84.5%              78.7%                                              
  Kappa (95% CI)              0.64 (0.57‐0.72)   0.59 (0.50‐0.67)   0.42 (0.33‐0.52)                                   

Abbreviation: CI, confidence interval; FAST3‐F, fibromyalgia assessment screening tool cumulative index (includes fatigue, self‐report painful joint count, and symptom checklist); FAST3‐P, fibromyalgia assessment screening tool cumulative index (includes pain, self‐report painful joint count, and symptom checklist); FAST4, fibromyalgia assessment screening tool cumulative index (includes pain, fatigue, self‐report painful joint count, and symptom checklist); FM, fibromyalgia; MDHAQ, multidimensional health assessment questionnaire; PSD, polysymptomatic distress scale; SSS, symptom severity scale; WPI, widespread pain index.

MDHAQ‐FM‐PSD is the sum of the MDHAQ‐FM‐SSS and MDHAQ‐FM‐WPI scores.
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Discussion {#acr211053-sec-0020}
==========

The present study extends previous reports that earlier MDHAQ versions provided clues to FM [21](#acr211053-bib-0021){ref-type="ref"}, [22](#acr211053-bib-0022){ref-type="ref"}, [46](#acr211053-bib-0046){ref-type="ref"}. The continuous MDHAQ‐FM‐PSD of similar or identical MDHAQ and 2011 FM criteria PSD items identifies FM comparably to the FM criteria, with a ROC AUC of 0.929. The cumulative indices FAST3‐P, FAST3‐F, and FAST4, which are based on the MDHAQ pain VAS, fatigue VAS, painful joint count, and/or symptom checklist, are more easily scored and associated with ROC AUCs greater than 0.924, virtually identical to the MDHAQ‐FM‐PSD. FAST3‐P and FAST3‐F scores of greater than or equal to 2 and FAST4 score greater than or equal to 3 appear to provide the optimal trade‐off of sensitivity and specificity for identifying FM in routine clinical practice. Ultimately, interpretation of questionnaire data depends on the clinician\'s judgment, as it is also true for laboratory and radiographic data.

A FAST on a MDHAQ to screen for FM status can be an advantage in the busy clinical setting, in which distribution of different questionnaires to patients with different diagnoses generally is not feasible. The most successful strategy involves all patients completing the same questionnaire [11](#acr211053-bib-0011){ref-type="ref"}. The MDHAQ/RAPID3 is informative in all rheumatic diseases in which it has been studied [23](#acr211053-bib-0023){ref-type="ref"}, [24](#acr211053-bib-0024){ref-type="ref"}, [25](#acr211053-bib-0025){ref-type="ref"}. The four‐page MDHAQ provides a useful intake questionnaire that includes questions on past illnesses, surgeries, family history, allergies, medications, and demographic data as well as all scales on the two‐page version [47](#acr211053-bib-0047){ref-type="ref"}. The four‐page "new patient" MDHAQ collects RAPID3 and a symptom checklist in new patients prior to a definitive diagnosis and/or in patients who do not have a definitive diagnosis, when they may be useful and when a disease‐specific questionnaire cannot be applied [47](#acr211053-bib-0047){ref-type="ref"}.

Most quantitative clinical rheumatology measures are designed to address inflammatory activity, with a raison d'être to control inflammation to prevent organ damage. Indices such as the DAS28, CDAI, and RAPID3 function well in selected patients in clinical trials and other clinical research but may be sensitive to organ damage and/or patient distress in routine care. For example, DAS28 = 5.1, CDAI = 26, and RAPID3 = 16, suggests high activity in a patient with no swollen joints (score of 0) and ESR of 10, but a tender joint count of 18, a pain VAS of 8, and a PATGL of 8. One report indicated that nonintensification of therapy according to "treat‐to‐target" in many patients with a moderate or high DAS28 was explained by recognition of high levels of damage or FM [18](#acr211053-bib-0018){ref-type="ref"}.

Many sites have abbreviated the MDHAQ to include only RAPID3 [48](#acr211053-bib-0048){ref-type="ref"}, although all reports from the authors of this report concerning RAPID3 have not suggested use without other MDHAQ scales [49](#acr211053-bib-0049){ref-type="ref"}. One reason seen in this and earlier reports is that patients with FM have higher RAPID3 scores than patients with other rheumatic diagnoses [23](#acr211053-bib-0023){ref-type="ref"}, but other MDHAQ scores may be clues to FM [22](#acr211053-bib-0022){ref-type="ref"}. The presence of secondary FM may explain persistently high indices and apparently poor responses to a treat‐to‐target strategy in RA [17](#acr211053-bib-0017){ref-type="ref"}, [18](#acr211053-bib-0018){ref-type="ref"}.

A full MDHAQ, which includes fatigue, painful joint count, a symptom checklist, recent medical history, etc, is completed by patients in 5‐10 minutes versus 2‐5 minutes for RAPID3. The time is the patient\'s; the process helps the patient prepare for the visit and ultimately saves time for both doctor and patient while improving documentation considerably [11](#acr211053-bib-0011){ref-type="ref"}, [49](#acr211053-bib-0049){ref-type="ref"}.

Several limitations are seen in our study. Only about 30% of questionnaires with complete data were entered into the database because of limited personnel to enter paper questionnaires. However, no selection was applied according to diagnosis or other characteristics. The data came from only one center, which does not specialize in FM, but FM is widespread in all rheumatology care. Similar observations have been made at another site in Australia [46](#acr211053-bib-0046){ref-type="ref"}.

The observations appear to be relevant, extending previous reports concerning MDHAQ clues to FM [21](#acr211053-bib-0021){ref-type="ref"}, [22](#acr211053-bib-0022){ref-type="ref"}. Neither the 2011/2016 FM criteria nor any FAST index invariably indicates FM, which is recognized as a spectrum of symptoms [50](#acr211053-bib-0050){ref-type="ref"}, because all quantitative data, whether from patient self‐report questionnaires, laboratory tests, or any other sources, require interpretation by a knowledgeable physician. A feasible clue to identify FM in routine care appears helpful, particularly in patients with other rheumatic diagnoses, but the ultimate diagnosis depends on the physician\'s judgment.

In summary, several FAST indices give similar results using 2011 FM criteria as external reference. The FAST3‐F may present an advantage of not including a pain VAS, so the three measures in RAPID3 are distinct from the three measures in the FAST3. Further research in larger numbers of patients, including longitudinal analyses, may identify whether a particular FAST index may be more informative than others for providing clues to FM in routine rheumatology care.
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